Prion Protein of Extracellular Vesicle Regulates the Progression of Colorectal Cancer (vol 13, 2144, 2021)

초록

The authors wish to make the following corrections to this paper [1]: The authors are sorry to report that the paper contains errors in Figures 6 and 7, and Supplemental Figure S12 and misses the information for these figures in the results (Section 3.4) in the recently published paper [1]. Due to unintentional errors made during the preparation of the figures, figure legends, and manuscript, the authors mistakenly used the unmatched values of Anti-PrP antibody dose or cetuximab dose in Figures 6 and 7, and Supplemental Figure S12. The authors wish to replace the correct values of the Anti-PrP antibody dose or Cetuximab dose in Figures 6 and 7, and Supplemental Figure S12 and to revise the figure legends and in the results (Section 3.4). Consequently, the authors wish to make the following corrections to the paper: In Section 2.4 “Cell Isolation Targeting PrPC using Magnetic Activated Cell Sorting”, we merged the two paragraphs of the original manuscript into one paragraph. It should be replaced with the following version: “Cell isolation by the expression of PrPC was sorted using manual magnetic activated cell sorting (MACS) according to the manufacturer’s protocol (Miltenyi Biotec, Bergisch Gladbach, Germany). Cells were incubated with human CD230 (PrP)-Biotin primary antibody, followed by a wash with MACS rinsing solution and attached to anti-Biotin MicroBeads secondary antibody. After another wash, a MACS LS column with an active magnetic field was used to sort and isolate the cells, which were used for flow cytometry analysis, spheroid formation, and RNA sequencing.” In Section 2.16 “Tumorigenesis in CRC Xenograft Mice Models”, the formula V = (a b2)/2.23 should be changed to V = (a b2)/2. In Section 2.18 “Immunofluorescence Staining”, the words “against HSPA1L and HIF-1 (Santa Cruz Biotechnology) or” were removed from the first sentence. In Section 3.4 “Co-Administration of 5FU and Anti-PrP Antibody Inhibits CRC Progression through Suppression of PrPC Level”, the first paragraph, we changed the value of Anti-PrP antibody dose from “5 or 50 mg” to “0.05 or 0.5 mg/kg”, value of cetuximab dose from “50 mg/kg” to “0.5 mg/kg”. The corrected Figures 6 and 7 and Supplemental Figure S12 are listed below: (image presented) © 2021 Global Research Online. All rights reserved.